No Data
No Data
Equillium Executive Sells $32,985 in Stock
Vivtex Enters New Research Agreement With Equillium to Develop GI-targeted Formulations for Its First-in-Class Oral, Bi-Specific Peptide Therapy
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
Equillium Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)